Home | My NASDAQ | Tools | Mobile | Company List | ETFs | Pre-Market Quotes Real-Time Quotes After Hours Quotes
Home > Quotes > CTIC > Company News
CTIC
CTIC
$0.91
*
0.01
negative
1.09%

*Data as of May 25, 2012   | Cell Therapeutics, Inc. | Industry: Consumer Durables | HQ: Washington, United States
 
 

Symbol List ViewsSymbol List Views

Stock DetailsStock Details

Stock DetailsCHARTS

Stock DetailsCOMPANY NEWS

Stock DetailsSTOCK ANALYSIS

Stock DetailsFUNDAMENTALS

Stock DetailsHOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 |  Sponsored

CTIC Press Releases

Share |


   


RBCC, Amarantus Move Forward with Joint Venture Discussions
05/16/2012 5:00AM - Business Wire

Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas
05/10/2012 2:30PM - PR Newswire

RBCC Target’s Brain Injury Treatment Awareness Campaign Reaches Milestone
05/04/2012 5:00AM - Business Wire

RBCC: Global Scientific Community Embraces New Parkinson’s Therapy
05/03/2012 5:00AM - Business Wire

RBCC Target Amarantus BioSciences Reports Positive Pre-Clinical Results of Parkinson’s Treatment
05/02/2012 5:00AM - Business Wire

Rainbow Biosciences, LLC Enters into Letter of Intent with Amarantus BioSciences to Advance Parkinson’s Disease Program
04/30/2012 5:00AM - Business Wire

RBCC: Link Between Parkinson’s and Alzheimer’s Could Greatly Increase Market for New Therapies
04/25/2012 5:00AM - Business Wire

Cell Therapeutics, Inc. (CTI) Reports First Quarter Financial Results and Milestones
04/20/2012 1:30AM - PR Newswire

Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
04/19/2012 8:00PM - PR Newswire

Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis
04/19/2012 1:30AM - PR Newswire

Cell Therapeutics, Inc. (CTI) to Host Conference Call April 19, 8:30 AM ET
04/18/2012 8:00PM - PR Newswire

RBCC: Global Market for Neurodegenerative Therapies to Exceed $43.4 Billion by 2015
04/10/2012 5:00AM - Business Wire

University of Washington's Neuro-Oncology Program to Investigate Cell Therapeutics' Drug Candidate OPAXIO™ (Paclitaxel Poliglumex) plus Radiotherapy for Glioblastoma Multiforme, a Highly Malignant Brain Cancer
03/27/2012 1:30AM - PR Newswire

RBCC: Michael J. Fox Foundation Invests $179 Million in the Fight Against Parkinson’s Disease
03/26/2012 5:00AM - Business Wire

RBCC Prepares to Join the $3 Billion Fight Against Parkinson’s Disease
03/23/2012 8:17AM - Business Wire

Cell Therapeutics and Keryx Biopharmaceuticals Hope for Help From the TREAT Act
03/22/2012 8:20AM - Market Wire

N3D Unveils the Next Generation of 3D Cell Culturing System
03/20/2012 5:00AM - Business Wire

RBCC Closes Deal with Game Changing Biotech Firm
03/15/2012 8:14AM - Business Wire

RBCC: Promising New Parkinson’s Therapies May Also Treat Brain Injuries
03/14/2012 5:00AM - Business Wire

Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones
03/07/2012 1:30AM - PR Newswire

Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End 2011 Financial Results on March 7
03/06/2012 1:30AM - PR Newswire

Growing Medical Need for Cancer and Inflammation Treatment Benefits Cell Therapeutics and Zalicus
03/02/2012 8:20AM - Market Wire